Spironolactone Tablet
Product Images NDC 53746-514

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 53746-514). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Of New York Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

20 (Spironolactone Tablets Usp 1)

Chemical structure of spironolactone, a corticosteroid derivative with a lactone ring and an acetate side chain. The structure shows multiple ring systems including a steroid backbone and an attached thioacetate group.*

FDA Label Image

10 (Spironolactone Tablets Usp 2)

A Kaplan-Meier survival curve comparing the probability of an outcome over 42 months between Spironolactone and placebo groups. The graph shows two lines, with the Spironolactone group (n=822) having a higher probability over time than the placebo group (n=841). The x-axis represents time in months, and the y-axis shows probability, with statistical significance indicated by a log-rank p value less than 0.001.*

FDA Label Image

2 (Spironolactone Tablets Usp 3)

A forest plot chart showing hazard ratios (HR) and 95% confidence intervals (CI) for various subgroups related to Spironolactone treatment effects compared to placebo. Subgroups are listed by age, sex, race, LVEF percentage, heart failure type, NYHA class, diabetes presence, serum creatinine levels, creatinine clearance, potassium levels, digoxin, ACEI, and beta blocker use. The plot visually compares Spironolactone versus placebo effectiveness across these categories.*

FDA Label Image

1 (Spironolactone Tablets Usp 4)

Spironolactone Tablets, USP 25 mg oral tablets, packaged as 30 tablets per container. The label shows NDC 53746-511-30 and indicates the product is manufactured by Amneal Pharmaceuticals Pvt. Ltd. in India and distributed by Amneal Pharmaceuticals LLC in New Jersey, USA. Storage instructions and dosage guidance reference attached literature.*

FDA Label Image

7 (Spironolactone Tablets Usp 5)

Spironolactone Tablets, USP 50 mg oral tablets packaging label showing a 30-tablet count. The label states the active ingredient Spironolactone, USP 50 mg per tablet, and includes storage instructions at 20° to 25°C. Manufactured by Amneal Pharmaceuticals Pvt. Ltd. in Ahmedabad, India, and distributed by Amneal Pharmaceuticals LLC in Bridgewater, NJ. The label includes the NDC number 53746-514-30 and the Amneal logo.*

FDA Label Image

13 (Spironolactone Tablets Usp 6)

Label for Spironolactone Tablets, USP 100 mg oral tablets by Amneal Pharmaceuticals. The bottle contains 30 tablets. The label includes the NDC 53746-515-30, manufacturer's and distributor's information, and dosage storage instructions at controlled room temperature. The tablet imprint 'AN 515' is shown.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.